Iqvia Holdings Inc Share Price Nyse
Equities
US74876Y1010
Biotechnology & Medical Research
Sales 2024 * | 1.55TCr 1,28600Cr | Sales 2025 * | 1.66TCr 1,37500Cr | Capitalization | 4.18TCr 3,47400Cr |
---|---|---|---|---|---|
Net income 2024 * | 133.6Cr 11TCr | Net income 2025 * | 157.6Cr 13TCr | EV / Sales 2024 * | 3.47 x |
Net Debt 2024 * | 1.19TCr 99TCr | Net Debt 2025 * | 1.17TCr 97TCr | EV / Sales 2025 * | 3.23 x |
P/E ratio 2024 * |
31.3
x | P/E ratio 2025 * |
26.3
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 70% |
Latest transcript on Iqvia Holdings Inc
Managers | Title | Age | Since |
---|---|---|---|
Ari Bousbib
CEO | Chief Executive Officer | 63 | 03/16/03 |
Ronald Bruehlman
DFI | Director of Finance/CFO | 63 | 01/20/01 |
James Berkshire
COO | Chief Operating Officer | 51 | 01/17/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Danhakl
BRD | Director/Board Member | 67 | 03/16/03 |
Colleen Goggins
BRD | Director/Board Member | 68 | 27/17/27 |
Ari Bousbib
CEO | Chief Executive Officer | 63 | 03/16/03 |
1st Jan change | Capi. | |
---|---|---|
+67.53% | 6.39TCr | |
+45.66% | 4.07TCr | |
-10.72% | 2.71TCr | |
+13.30% | 2.65TCr | |
-22.79% | 1.87TCr | |
+4.70% | 1.27TCr | |
+24.10% | 1.21TCr | |
+27.41% | 1.21TCr | |
-8.12% | 1.12TCr |